Loading…

compare compounds

class, effects, and the receptor fingerprint, side by side; add up to four, then source the whole stack

reading the marksactivatesblocks / inhibitsmodulates

06ACh

Nicotine

CholinergicNicotinic AgonistStimulant

Alpha-4 beta-2 (α4β2) nAChRagonist (high-affinity subtype)

strongKi ~1.05 nM

Alpha-6-containing (α6β2*) nAChR on dopamine terminalsagonist

moderate

Alpha-7 (α7) nAChRagonist (low-affinity, rapidly desensitizing)

weakKi ~4000 nM

Alpha-3 beta-4 (α3β4) nAChR (autonomic ganglia + adrenal medulla)agonist

moderate

Mesolimbic dopamine release (VTA → nucleus accumbens)indirect agonist via nAChR

strong

α4β2 receptor upregulation + desensitization (chronic exposure)functional desensitization then increased receptor number

strong

06ACh

CholinergicNicotinic Partial AgonistSmoking Cessation

Alpha4beta2 nicotinic (a4b2 nAChR)high-affinity partial agonist

strongEC50 ~2.3 uM, ~13% efficacy vs ACh (functional); sub-nanomolar binding affinity

Alpha7 nicotinic (a7)full agonist

moderateEC50 ~18 uM, ~93% efficacy

Alpha3beta4 nicotinic (a3b4)partial agonist

moderateEC50 ~55 uM, ~75% efficacy

Alpha6beta2* nicotinic (a6-containing)weak partial agonist

weakefficacy <10% vs ACh

Alpha3beta2 nicotinic (a3b2)weak partial agonist

weakefficacy <10%

Add compound

no matches for “”

OverallNo data

checking Nicotine and Varenicline: no notable interaction flagged; they read as broadly independent.

Nicotine + Varenicline
No data
no notable interaction flagged; these look broadly independent.

General educational info, not medical advice.